> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Genentech’s Enspryng Regulatory Review Period
- URL: https://www.fdaweb.com/genentechs-enspryng-regulatory-review-period/
- Published: 2022-07-14T12:00:00.000Z
- Updated: 2026-09-14T17:51:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152275

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Genentech’s Enspryng (satralizumab-mwge), indicated for treating neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive. The regulatory review period is 2,495 days, of which 2,128 days occurred during the testing phase and 367 days occurred during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14930.pdf?ref=fdaweb.com).